
[I]. antibodies that have different sequences from PL&RL£º
warningList= ['otlertuzumab|Heavy', 'vadastuximab talirin|Light', 'tenatumomab|Heavy', 'tenatumomab|Light', 'foravirumab|Heavy', 'rafivirumab|Heavy', 'rafivirumab|Light', 'ascrinvacumab|Heavy']


1.. quite different 
RL60 >tenatumomab|Heavy
EIQLQQSGPE LVKPGASVKV SCKASGYAFT SYNMYWVKQS HGKSLEWIGY 50
IDPYNGVTSY NQKFKGKATL TVDKSSSTAY MHLNSLTSED SAVYYCARGG 100
GSIYYAMDYW GQGTSVTVSS AKTTPPSVYP LAPGCGDTTG SSVTLGCLVK 150
GYFPESVTVT WNSGSLSSSV HTFPALLQSG LYTMSSSVTV PSSTWPSQTV 200
TCSVAHPASS TTVDKKLEPS GPISTINPCP PCKECHKCPA PNLEGGPSVF 250
IFPPNIKDVL MISLTPKVTC VVVDVSEDDP DVQISWFVNN VEVHTAQTQT 300
HREDYNSTIR VVSTLPIQHQ DWMSGKEFKC KVNNKDLPSP IERTISKIKG 350
LVRAPQVYIL PPPAEQLSRK DVSLTCLVVG FNPGDISVEW TSNGHTEENY 400
KDTAPVLDSD GSYFIYSKLN MKTSKWEKTD SFSCNVRHEG LKNYYLKKTI 450
SRSPGK
PL98 >tenatumomab|Heavy
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYVMSWVRQA PGKGLEWVAT 50
ISSGGSYTYY PDSVKGRFTI SRDNAKNTLY LQMNSLRAED TAVYYCARRG 100
DSMITTDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK 449


2. quite different
RL60 >tenatumomab|Light
DIVMTQAAPS VPVTPGESVS ISCRSSKSLL HSNGNTYLYW FLQRPGQSPQ 50
LLIYRMSNLA SGVPDRFSGS GSGTAFTLRI SRVEAEDVGV YYCMQHLEYP 100
LTFGAGTKLE LKRADAAPTV SIFPPSSEQL TSGGASVVCF LNNFYPKDIN 150
VKWKIDGSER QNGVLNSWTD QDSKDSTYSM SSTLTLTKDE YERHNSYTCE 200
ATHKTSTSPI VKSFNRNEC
PL98 >tenatumomab|Heavy
DIQMTQSPSS LSASVGDRVT ITCKASQDVG TAVAWYQQKP GKAPKLLIYW 50'
ASTRHTGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSSYRTFGQG 100'
TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150'
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200'
SSPVTKSFNR GEC


3. only the first residue, in PL99, E is a modified residue
RL61 >foravirumab|Heavy
QVQLVESGGG AVQPGRSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVAV 50
ILYDGSDKFY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVA 100
VAGTHFDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPG 448
PL99 >foravirumab|Heavy
EVQLVESGGG AVQPGRSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVAV 50
ILYDGSDKFY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVA 100
VAGTHFDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPG


4. only the first residue modified
RL61 >rafivirumab|Heavy
QVQLVQSGAE VKKPGSSVKV SCKASGGTFN RYTVNWVRQA PGQGLEWMGG 50
IIPIFGTANY AQRFQGRLTI TADESTSTAY MELSSLRSDD TAVYFCAREN 100
LDNSGTYYYF SGWFDPWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA 150
ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS 200
SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV 250
FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK 300
PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK 350
GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN 400
YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS 450
LSLSPG 456
PL99 >rafivirumab|Heavy
EVQLVQSGAE VKKPGSSVKV SCKASGGTFN RYTVNWVRQA PGQGLEWMGG 50
IIPIFGTANY AQRFQGRLTI TADESTSTAY MELSSLRSDD TAVYFCAREN 100
LDNSGTYYYF SGWFDPWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA 150
ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS 200
SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV 250
FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK 300
PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK 350
GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN 400
YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS 450
LSLSPG 456


5. only the first residue modified
RL61 >rafivirumab|Light
QSALTQPRSV SGSPGQSVTI SCTGTSSDIG GYNFVSWYQQ HPGKAPKLMI 50
YDATKRPSGV PDRFSGSKSG NTASLTISGL QAEDEADYYC CSYAGDYTPG 100
VVFGGGTKLT VLGQPKAAPS VTLFPPSSEE LQANKATLVC LISDFYPGAV 150
TVAWKADSSP VKAGVETTTP SKQSNNKYAA SSYLSLTPEQ WKSHRSYSCQ 200
VTHEGSTVEK TVAPTECS
PL99 >rafivirumab|Light
ESALTQPRSV SGSPGQSVTI SCTGTSSDIG GYNFVSWYQQ HPGKAPKLMI 50'
YDATKRPSGV PDRFSGSKSG NTASLTISGL QAEDEADYYC CSYAGDYTPG 100'
VVFGGGTKLT VLGQPKAAPS VTLFPPSSEE LQANKATLVC LISDFYPGAV 150'
TVAWKADSSP VKAGVETTTP SKQSNNKYAA SSYLSLTPEQ WKSHRSYSCQ 200'
VTHEGSTVEK TVAPTECS

6.only the last residue modified
RL75 >ascrinvacumab|Heavy 
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGEYYWNWIRQHPGKGLEWI
GYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARE
SVAGFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDY
FPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYT
CNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMI
SRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVV
SVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPP
SREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGS
FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNKYTQKSLSLSPGK
PL >ascrinvacumab|Heavy 
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGEYYWNWIRQHPGKGLEWI
GYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARE
SVAGFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDY
FPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYT
CNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMI
SRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVV
SVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPP
SREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGS
FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG








[II].Antibodies that really have no sequence:

1.denosumab
2.ipilimumab
3.iratumumab 
4.nimotuzumab  
5.ocrelizumab  
6.stamulumab 
7.tucotuzumab celmoleukin 
8.canakinumab
9.tremelimumab
10.tanezumab
11.ustekinumab 



#notes#
RL_all.faa  no seq:
1 . denosumab - no sequence   -noseq
2 . ipilimumab - no sequence  -noseq
3 . iratumumab - no sequence  -noseq
4 . nimotuzumab - no sequence -noseq
5 . ocrelizumab - no sequence -noseq
6 . stamulumab - no sequence  -noseq
7 . tadocizumab - no sequence -***has sequence; Fab fragment(VH+VL)
8 . tucotuzumab celmoleukin -no sequence 
                              -noseq
9 . efungumab - no sequence   -***scFv VH+VL;
                              -???last five residue[hhhhh]|
10 . motavizumab - no sequence-***VH+VL.
11 . canakinumab - no sequence-noseq
12 . tremelimumab - no sequence -noseq
13 . anrukinzumab - no sequence -***VH+VL
14 . conatumumab - no sequence  -***VH+VL
15 . tanezumab - no sequence    -noseq
16 . ustekinumab - no sequence  -noseq
17 . blinatumomab - no sequence -***ScFv-ScFV, VL+VH+VH+VL
18 . oportuzumab monatox - no sequence -***scFV protein fusion, VL-VH-protein
19 . moxetumomab pasudotox - no sequence -***Fv fused
20 . radretumab - no sequence   -***scFv 
21 . ozoralizumab - no sequence -***VH-VH-VH
22 . caplacizumab - no sequence -***VH-VH
23 . solitomab - no sequence    -***scFv-scFv ??? how to mark it 
24 . lulizumab pegol - no sequence -***VL
25 . pasotuxizumab - no sequence   -***ScFv-ScFv ??? how to mark it 
26 . brolucizumab - no sequence   -***ScFv  ??? how to mark it 
27 . ascrinvacumab - no sequence  -***ScFv |imaged
28 . bevacizumab beta - no sequence -***  |imaged
29 . blontuvetmab - no sequence      -***  |imaged
30 . carotuximab - no sequence    -*** |imaged
31 . crotedumab - no sequence     -*** |imaged
32 . lanadelumab - no sequence  -*** |imaged
33 . laprituximab - no sequence -*** |imaged
34 . laprituximab emtansin - no sequence -*** |imaged
                                         ??? same as 33. keep or ignore?
35 . naratuximab - no sequence    -*** |imaged
36 . naratuximab emtansin - no sequence -*** |imaged
37 . navicixizumab - no sequence  -*** |imaged   !!!HAVE TXT IN PL114
38 . prezalumab - no sequence    -*** |imaged
39 . rivabazumab - no sequence   -*** |imaged
40 . tamtuvetmab - no sequence   -*** |imaged
41 . vadastuximab - no sequence  -*** |imaged
42 . vobarilizumab - no sequence  -*** ScFv VHVH|imaged

if ScFV: marked as "mab| "
